您的位置:首页 > 产品中心 > 183322-45-4, PD153035 盐酸盐
PD153035 盐酸盐
PD153035 hydrochloride
产品价格查看更多规格...
产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
3179597 | 5 MG | 994 | |||
3179597 | 25 MG | 3500 |
产品别名
183322-45-4
PD153035 盐酸盐
PD153035 hydrochloride
4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline Hydrochloride
AG 1517
SU 5271
ZM 252868
PD 153035
结构式
基本信息
Empirical Formula【经验(实验)分子式】 | C16H14BrN3O2 · HCl |
Molecular weight | 396.67 |
MDL number | MFCD01074805 |
PubChem Substance ID【PubChem化学物质编号】 | 329825555 |
NACRES | NA.77 |
Biochem/physiol Actions【生化/生理作用】 | PD153035 is apotent and selective ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase EGFR. |
Features and Benefits【特点和优势】 | This compound is featured on the EGFR page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here. This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm. |
产品性质
Quality Level【质量水平】 | 100 |
Assay【测定】 | ≥98% (HPLC) |
form【形式】 | powder |
color【颜色】 | white to beige |
solubility【溶解性】 | DMSO: 2 mg/mL, clear (warmed) |
storage temp.【储存温度】 | 2-8℃ |
SMILES string | Cl.COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC |
InChI | 1S/C16H14BrN3O2.ClH/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11;/h3-9H,1-2H3,(H,18,19,20);1H |
InChI key | ZJOKWAWPAPMNIM-UHFFFAOYSA-N |
packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
Pictograms【象形图】 | GHS05,GHS06 |
Signal word【警示用语:】 | Danger |
Hazard Statements | H301 - H315 - H318 - H335 |
Precautionary Statements | P280 - P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 + P310 |
Hazard Classifications【危险分类】 | Acute Tox. 3 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3 |
Target Organs【靶器官】 | Respiratory system |
Storage Class Code【储存分类代码】 | 6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects |
WGK | WGK 3 |